NVSEF News and Press, Novartis Ag Basel Akt From 04/27/21

Novartis AG (NVS) Q1 2021 Earnings Conference Call April 27, 2021 8:00 AM ET Company Participants Samir Shah – Global Head-Investor Relations Vas Narasimhan – Chief Executive Officer Marie-France Tschudin – President-Novartis Pharmaceuticals Richard Saynor – Chief ...

The following slide deck was published by Novartis AG in conjunction with their 2021 Q1 earnings call. For further details see: Novartis AG 2021 Q1 - Results - Earnings Call Presentation

In the past few years, the CAR-T, gene-based, regenerative medicines sector is becoming prominent. The premier logistic provider, Cryoport, is leading at the forefront of this innovation. When I first made my recommendation back in January 2018, Cryoport was trading at only $6.97....

Takeda is a Japanese healthcare company that pays consistent dividends. The company is trying to achieve growth using acquisition and research, and so far fails. The company is not consistent enough to be a good income investment. For further details see: Takeda Is A Med...

CRSR is one of the few companies that hold a patent to the 2020 Nobel Prize CRISPR technology. The company's pipeline includes potential blockbuster medicines, demonstrating a more aggressive strategy compared to Editas Medicine, one of its main competitors. The recent correction ...

EDIT has an exclusive patent on the Nobel Prize-winning CRISPR technology that has the potential to change the biotech industry fundamentally. CRISPR is an affordable, clean and effective technology that puts human genes under scientists' full control. If the FDA approves EDIT's l...

The field of gene editing remains in its infancy with multiple players jockeying for position. The concept is to use the latest in technology to "fix" the genetic abnormality by repairing with a non-defective gene. The technology is now evolving to human trials that will shed ligh...

Kahn Brothers’ 13F portfolio value increased from $528M to $579M this quarter. New York Community Bancorp, VOXX International, BlackBerry, and Patterson-UTI Energy were decreased during the quarter. The portfolio continues to be very concentrated with the top five positions...

Fisher’s 13F portfolio value increased from $117.8B to $133.5B in Q4 2020. They increased Alphabet and Total SA during the quarter. Fisher has a number of small positions in several ETFs/ETNs. For further details see: Tracking Ken Fisher's Fisher Asset Management ...

Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers. BOLT has produced early efficacy results for its lead program and has an impressive investor syndicate, so the IPO is worth consideration...